Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The Company’s pipeline focuses in three strategic therapeutic areas (STArs): genetic medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; cardio-metabolic disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. It is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Employee Rating

4.3More
TypePublic
HQCambridge, US
Founded2002
Size (employees)514 (est)
Websitealnylam.com
Alnylam Pharmaceuticals was founded in 2002 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Alnylam Pharmaceuticals

Karen Anderson

Karen Anderson

SVP Chief Human Resources Officer
Barry Greene

Barry Greene

President
Yvonne Greenstreet

Yvonne Greenstreet

COO
Pushkal Garg

Pushkal Garg

Chief Medical Officer
Laurie Keating

Laurie Keating

SVP, General Counsel, and Secretary
John Maraganore

John Maraganore

CEO
Show more

Alnylam Pharmaceuticals Office Locations

Alnylam Pharmaceuticals has offices in Cambridge, Zug and Windsor and Maidenhead
Cambridge, US (HQ)
300 Third St
Zug, CH
19 Dammstrasse
Windsor and Maidenhead, GB
Braywick Rd
Show all (3)
Report incorrect company information

Alnylam Pharmaceuticals Financials and Metrics

Alnylam Pharmaceuticals Revenue

USD

Revenue (Q3, 2018)

2.1m

Gross profit (Q3, 2018)

1.9m

Gross profit margin (Q3, 2018), %

93.4%

Net income (Q3, 2018)

(245.3m)

EBIT (Q3, 2018)

(254.6m)

Market capitalization (14-Dec-2018)

7.8b

Closing stock price (14-Dec-2018)

77.1

Cash (30-Sep-2018)

316.6m

EV

7.5b
Alnylam Pharmaceuticals's current market capitalization is $7.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

27.2mwdxefcqufszuzezftuxetqsqxt60.6m89.4m199.4m

R&D expense

113.0m276.5m382.4m390.6m

Operating expense total

140.1m337.1m471.7m590.0m

EBIT

(92.9m)(405.0m)(296.0m)(424.6m)(500.1m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

2.1m

Cost of goods sold

137.0k

Gross profit

1.9m

Gross profit Margin, %

93%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

53.2m75.2m180.9m193.6m645.4m

Accounts Receivable

17.9m

Inventories

3.9m9.7m16.6m21.7m

Current Assets

254.0m746.4m1.1b671.9m1.8b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

11.8m350.6m80.7m82.7m306.6m151.3m149.2m231.3m271.1m168.5m171.1m408.7m202.0m396.1m361.5m316.6m

Accounts Receivable

3.4m

Inventories

11.1m

Current Assets

199.2m674.1m665.1m643.0m1.1b1.0b1.0b1.1b888.1m747.6m597.2m960.7m993.4m1.7b1.5b1.3b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(89.2m)(360.4m)(290.1m)(410.1m)(490.9m)

Depreciation and Amortization

10.2m11.9m19.1m15.1m13.4m

Inventories

Accounts Payable

1.8m8.8m1.7m10.1m(4.9m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(56.9m)(250.9m)(295.0m)(339.0m)(50.8m)(122.6m)(76.8m)(103.0m)(193.1m)(297.2m)(107.3m)(225.7m)(348.6m)(141.2m)(304.8m)(550.1m)

Depreciation and Amortization

7.6m5.5m8.6m8.7m4.6m8.6m12.1m3.0m6.1m9.7m3.2m

Inventories

(10.4m)

Accounts Payable

(1.3m)121.0k(826.0k)15.5m(1.2m)14.3m347.0k(3.6m)(1.5m)(11.1m)(8.3m)(17.3m)(9.0m)(9.7m)(650.0k)
USDY, 2018

EV/EBIT

-29.5 x

EV/CFO

-18.2 x

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Alnylam Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Alnylam Pharmaceuticals Company Life and Culture

Report incorrect company information

Alnylam Pharmaceuticals Frequently Asked Questions

  • When was Alnylam Pharmaceuticals founded?

    Alnylam Pharmaceuticals was founded in 2002.

  • Who are Alnylam Pharmaceuticals key executives?

    Alnylam Pharmaceuticals's key executives are Karen Anderson, Barry Greene and Yvonne Greenstreet.

  • How many employees does Alnylam Pharmaceuticals have?

    Alnylam Pharmaceuticals has 514 employees.

  • Who are Alnylam Pharmaceuticals competitors?

    Competitors of Alnylam Pharmaceuticals include Moderna Therapeutics, Olainfarm and Navitor Pharmaceuticals.

  • Where is Alnylam Pharmaceuticals headquarters?

    Alnylam Pharmaceuticals headquarters is located at 300 Third St, Cambridge.

  • Where are Alnylam Pharmaceuticals offices?

    Alnylam Pharmaceuticals has offices in Cambridge, Zug and Windsor and Maidenhead.

  • How many offices does Alnylam Pharmaceuticals have?

    Alnylam Pharmaceuticals has 3 offices.